Dr Reddy's Laboratories: Prepared for the journey ahead
` Balanced portfolio to deliver 16% revenue CAGR for 2013-15E
` Stable financial performance: 11% upside. Upgrade to ADD
` Diverse research efforts provide long-term visibility
` Key risks: Approval delays, competition, price controls
�� -->
Kotak report link:
http://www.kotaksecurities.com/pdf/indiadaily/indiadaily27092012ua.pdf
No comments:
Post a Comment